Atlas Venture Life Science Advisors LLC Sells 97,630 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO)

Atlas Venture Life Science Advisors LLC trimmed its holdings in Spero Therapeutics, Inc. (NASDAQ:SPRO) by 24.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 305,255 shares of the company’s stock after selling 97,630 shares during the quarter. Spero Therapeutics makes up about 0.0% of Atlas Venture Life Science Advisors LLC’s portfolio, making the stock its 13th biggest position. Atlas Venture Life Science Advisors LLC owned 0.56% of Spero Therapeutics worth $314,000 as of its most recent SEC filing.

Analyst Upgrades and Downgrades

SPRO has been the subject of several research reports. Evercore ISI cut shares of Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price objective for the company. in a research report on Friday, December 20th. TD Cowen reiterated a “hold” rating on shares of Spero Therapeutics in a report on Monday, November 18th. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Spero Therapeutics in a report on Thursday, January 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a report on Friday, November 15th.

Spero Therapeutics Stock Performance

NASDAQ SPRO opened at $0.77 on Thursday. The company has a market cap of $41.99 million, a PE ratio of 11.00 and a beta of 0.68. The firm’s 50 day moving average price is $0.89 and its 200-day moving average price is $1.12. Spero Therapeutics, Inc. has a 52-week low of $0.74 and a 52-week high of $1.89.

Insider Activity at Spero Therapeutics

In other news, CEO Sath Shukla sold 155,333 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $0.78, for a total transaction of $121,159.74. Following the completion of the sale, the chief executive officer now owns 1,736,883 shares in the company, valued at approximately $1,354,768.74. This represents a 8.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ankit Mahadevia sold 69,219 shares of the business’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $0.78, for a total value of $53,990.82. Following the transaction, the director now owns 689,866 shares in the company, valued at approximately $538,095.48. This trade represents a 9.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 245,241 shares of company stock valued at $191,288 over the last quarter. 4.52% of the stock is owned by corporate insiders.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.